This study aimed at comparing the efficacy of nitazoxanide-based triple therapy versus standard triple therapy for eradication of Helicobacter pylori infection in children at a tertiary care hospital.

The findings could guide clinical practice and influence guidelines, improving the management of H. pylori infections in the pediatric population. Not much local data also exists comparing the effectiveness of adding nitazoxanide to the standard triple therapy in children with H. pylori infection. If nitazoxanide-based therapy proves superior, it could reduce the incidence of antibiotic resistance associated with standard triple therapy.

Inclusion Criteria:

• Any gender
• Aged 2 to 12 years
• With symptoms like abdominal pain, nausea, vomiting, or other related gastrointestinal symptoms
• Diagnosed with H. pylori based on urea breath test

Exclusion Criteria:

• Liver cirrhosis
• Renal impairment
• Previous gastric or duodenal surgery or malignancy
• History of receiving H. pylori treatment
• Past 6 weeks history of using antacids, H2 receptor antagonists, anticoagulants, or antibiotics

Data can be shared on a reasonable request.